- Title
- P025: RADAR: An international phase III, PET response-adapted, randomised trial in progress, comparing ABVD±ISRT with brentuximab vedotin+AVD±ISRT in patients with previously untreated limited-stage classical Hodgkin lymphoma
- Creators
- John Radford - University of ManchesterToyin Adedayo - Cancer Research UK and University College London, Clinical Trials Centre, London, UKArzhang Ardavan - Patient Representative, Oxford, UKSally F. Barrington - Kings College London GSTT PET Imaging Centre, London, UKLeanne Berkahn - Auckland City HospitalStephane Chauvie - S. Croce et Carle Hospital, Cuneo, ItalyLaura Clifton-Hadley - Cancer Research UK and University College London, Clinical Trials Centre, London, UKGraham P. Collins - University of OxfordMichael Crump - University Health network, Toronto, CanadaDavid Cutter - University of OxfordDarren Edwards - Cancer Research UK and University College London, Clinical Trials Centre, London, UKMartin Hutchings - RigshospitaletTim Illidge - University of ManchesterAmy A. Kirkwood - Cancer Research UK and University College London, Clinical Trials Centre, London, UKKim Linton - University of ManchesterCraig H. Moskowitz - Sylvester Comprehensive Cancer CenterPip Patrick - Cancer Research UK and University College London, Clinical Trials Centre, London, UKBeth Phillips - University of ManchesterLois Shepherd - Queen's UniversitySanne Tonino - Amsterdam University Medical Centre, Amsterdam, NetherlandsJudith Trotman - Concord Repatriation General HospitalJoanna Williams - University of ManchesterNicole Wong Doo - Concord Repatriation General Hospital
- Publication Details
- HemaSphere, Vol.6(Suppl), pp.12-13
- Publisher
- Lippincott Williams & Wilkins
- Academic Unit
- Miller School of Medicine; UMMG Department of Medicine
- Language
- English
- Resource Type
- Journal article
- Record Identifier
- 991031786521002976
Journal article
P025: RADAR: An international phase III, PET response-adapted, randomised trial in progress, comparing ABVD±ISRT with brentuximab vedotin+AVD±ISRT in patients with previously untreated limited-stage classical Hodgkin lymphoma
HemaSphere, Vol.6(Suppl), pp.12-13
2022-10-03
Metrics
7 Record Views